Holen Sie sich die Stockscreener-App
84.75
0.74%
-0.63
Vorhandelsmarkt:
85.17
0.42
+0.50%
Schlusskurs vom Vortag:
$85.38
Offen:
$85.55
24-Stunden-Volumen:
1.40M
Relative Volume:
0.82
Marktkapitalisierung:
$16.55B
Einnahmen:
$4.58B
Nettoeinkommen (Verlust:
$870.87M
KGV:
19.27
EPS:
4.3988
Netto-Cashflow:
$945.58M
1W Leistung:
-1.77%
1M Leistung:
-0.99%
6M Leistung:
+43.99%
1J Leistung:
+28.88%
1-Tages-Spanne:
$84.14
$85.92
1-Wochen-Bereich:
$84.14
$88.30
52-Wochen-Spanne:
$53.56
$88.66
Incyte Corp Stock (INCY) Company Profile
Firmenname
Incyte Corp
Sektor
Branche
Telefon
(302) 498-6700
Adresse
1801 AUGUSTINE CUT-OFF, WILMINGTON, DE
Vergleichen Sie INCY mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
INCY
Incyte Corp
|
84.75 | 16.67B | 4.58B | 870.87M | 945.58M | 4.3988 |
|
VRTX
Vertex Pharmaceuticals Inc
|
414.86 | 107.98B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.95 | 59.07B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
569.90 | 59.76B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
804.90 | 49.19B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
335.80 | 38.56B | 4.56B | -176.77M | 225.30M | -1.7177 |
Incyte Corp Stock (INCY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-08 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2025-08-06 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2025-08-01 | Eingeleitet | Barclays | Overweight |
| 2025-06-16 | Hochstufung | Stifel | Hold → Buy |
| 2025-03-18 | Herabstufung | Guggenheim | Buy → Neutral |
| 2025-03-18 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2024-12-17 | Eingeleitet | UBS | Neutral |
| 2024-10-29 | Hochstufung | BofA Securities | Neutral → Buy |
| 2024-10-01 | Eingeleitet | Wolfe Research | Outperform |
| 2024-09-18 | Herabstufung | Truist | Buy → Hold |
| 2024-07-02 | Herabstufung | BMO Capital Markets | Market Perform → Underperform |
| 2024-05-23 | Eingeleitet | Deutsche Bank | Hold |
| 2024-04-23 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2024-02-23 | Eingeleitet | Jefferies | Buy |
| 2024-02-14 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2023-12-13 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2023-12-04 | Hochstufung | Guggenheim | Neutral → Buy |
| 2023-11-21 | Herabstufung | Goldman | Buy → Neutral |
| 2023-07-25 | Eingeleitet | Citigroup | Buy |
| 2023-05-04 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-04-10 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-03-24 | Hochstufung | SVB Securities | Underperform → Market Perform |
| 2023-01-31 | Eingeleitet | Piper Sandler | Overweight |
| 2022-08-03 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2022-08-03 | Herabstufung | Guggenheim | Buy → Neutral |
| 2022-07-28 | Eingeleitet | Wells Fargo | Equal Weight |
| 2022-02-09 | Herabstufung | SVB Leerink | Mkt Perform → Underperform |
| 2022-01-18 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2021-07-20 | Hochstufung | The Benchmark Company | Hold → Buy |
| 2021-02-10 | Herabstufung | SVB Leerink | Mkt Perform → Underperform |
| 2021-01-07 | Eingeleitet | Truist | Buy |
| 2021-01-04 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-06-16 | Eingeleitet | The Benchmark Company | Hold |
| 2020-05-06 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-04-29 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-04-01 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-03-24 | Fortgesetzt | William Blair | Outperform |
| 2020-03-13 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2020-02-04 | Fortgesetzt | BofA/Merrill | Neutral |
| 2020-01-03 | Bestätigt | BMO Capital Markets | Market Perform |
| 2020-01-03 | Herabstufung | Mizuho | Buy → Neutral |
| 2020-01-02 | Herabstufung | Guggenheim | Buy → Neutral |
| 2019-10-03 | Eingeleitet | Mizuho | Buy |
| 2019-09-12 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2019-09-05 | Hochstufung | JMP Securities | Mkt Perform → Mkt Outperform |
| 2019-09-05 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2019-09-05 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2019-05-21 | Eingeleitet | Credit Suisse | Neutral |
| 2019-05-03 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2019-04-11 | Eingeleitet | Stifel | Hold |
| 2019-04-03 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-01-24 | Hochstufung | William Blair | Mkt Perform → Outperform |
Alle ansehen
Incyte Corp Aktie (INCY) Neueste Nachrichten
What 14 Analyst Ratings Have To Say About Incyte - Benzinga
Sun Pharma Attacks Incyte Patents In Alopecia Drug Battle - Law360
INCY: JP Morgan Raises Price Target to $89, Maintains Neutral Ra - GuruFocus
Incyte (NASDAQ:INCY) Given Hold (C+) Rating at Weiss Ratings - MarketBeat
Incyte Corporation $INCY Shares Purchased by Shell Asset Management Co. - MarketBeat
Can Incyte Corporation rally from current levels2025 Year in Review & Weekly Watchlist for Consistent Profits - newser.com
Is Incyte Corporation stock a safe buy before earnings2025 Technical Overview & Smart Investment Allocation Insights - newser.com
Incyte Faces Revenue Squeeze As Jakafi Patent Winds Down - Finimize
Incyte to Report Third Quarter Financial Results - Business Wire
Incyte stock rating downgraded to Perform by Oppenheimer - Investing.com
Will Incyte (INCY) Beat Estimates Again in Its Next Earnings Report? - Yahoo Finance
Incyte Corporation (INCY) Appoints New Principal Financial Officer - GuruFocus
Is Incyte Corporation (ICY) stock a defensive play amid uncertaintyTrade Signal Summary & Free Fast Gain Swing Trade Alerts - newser.com
How to use Fibonacci retracement on Incyte CorporationPortfolio Update Summary & Target Return Focused Stock Picks - newser.com
Grimes & Company Inc. Has $12.26 Million Position in Incyte Corporation $INCY - MarketBeat
Price action breakdown for Incyte CorporationJuly 2025 PostEarnings & Step-by-Step Swing Trade Plans - newser.com
Legacy Trust Cuts Holdings in Incyte Corporation $INCY - MarketBeat
Published on: 2025-10-05 05:30:49 - newser.com
Why Incyte Corporation (ICY) stock is favored by hedge funds2025 Stock Rankings & Community Consensus Stock Picks - newser.com
How Incyte Corporation (ICY) stock reacts to stronger dollar2025 Price Targets & Free Long-Term Investment Growth Plans - newser.com
Institutional scanner results for Incyte Corporation2025 Growth vs Value & High Accuracy Buy Signal Tips - newser.com
Incyte Grants Equity Awards to New Chief Strategy Officer David Gardner - MyChesCo
Incyte Appoints Thomas Tray as Financial Officer - The Globe and Mail
Impact Investors Inc Has $209,000 Stock Position in Incyte Corporation $INCY - MarketBeat
Incyte (NASDAQ:INCY) Raised to "Strong-Buy" at Wall Street Zen - MarketBeat
Will Incyte's (INCY) New Strategy Team and CALR Antibody Hopes Reshape Its Long-Term Story? - simplywall.st
Incyte appoints Thomas Tray as principal financial officer - StreetInsider
Incyte (INCY) Price Target Lifted on CALR Antibody Program Optimism - MSN
Incyte (INCY) Is Up 5.7% After FDA Pediatric Opzelura Approval and Leadership Updates Has the Bull Case Changed? - simplywall.st
Incyte Names Dave Gardner Chief Strategy Officer Amid Leadership Transition - MyChesCo
Will Incyte Corporation stock outperform value stocksWeekly Gains Report & Community Consensus Trade Alerts - newser.com
Backtesting results for Incyte Corporation trading strategiesMarket Risk Summary & Community Consensus Picks - newser.com
Incyte Corporation stock hits 52-week high at 88.19 USD By Investing.com - Investing.com Australia
FDA Expands Approval of Incyte’s Opzelura to Treat Pediatric Atopic Dermatitis - MSN
Incyte Corporation stock hits 52-week high at 88.19 USD - Investing.com
Robeco Institutional Asset Management B.V. Has $162.51 Million Stock Position in Incyte Corporation $INCY - MarketBeat
2 Reasons to Like INCY and 1 to Stay Skeptical - The Globe and Mail
Lbp Am Sa Has $12.17 Million Stock Position in Incyte Corporation $INCY - MarketBeat
Public Employees Retirement System of Ohio Buys 3,951 Shares of Incyte Corporation $INCY - MarketBeat
Poinciana Advisors Group LLC Makes New Investment in Incyte Corporation $INCY - MarketBeat
Will Incyte Corporation (ICY) stock see insider accumulationQuarterly Profit Report & AI Enhanced Market Trend Forecasts - newser.com
Patton Albertson Miller Group LLC Acquires 5,497 Shares of Incyte Corporation $INCY - MarketBeat
Patton Fund Management Inc. Takes $254,000 Position in Incyte Corporation $INCY - MarketBeat
China Medical System (867.HK; 8A8.SG) Positive Results from China Phase 3 Clinical Trial of Innovative Drug Ruxolitinib Cream with AD Indication - GlobeNewswire Inc.
Candlestick signals on Incyte Corporation stock todayMarket Performance Recap & Breakout Confirmation Alerts - newser.com
Incyte (INCY) Advances Clinical Trials for Povorcitinib Across Multiple Conditions - Yahoo Finance
INCY's Q4 Earnings Miss Mark, Revenues Beat on Higher Product Sales - MSN
Jim Cramer Calls Incyte “Way Too Cheap” - Yahoo Finance
Ruffer LLP Sells 9,988 Shares of Incyte Corporation $INCY - MarketBeat
Incyte (INCY) Gets a Hold from RBC Capital - The Globe and Mail
Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)September 24, 2025 - biospace.com
Finanzdaten der Incyte Corp-Aktie (INCY)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.96%
1.60%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):